Last reviewed · How we verify
Notch signaling pathway inhibitor MK0752
At a glance
| Generic name | Notch signaling pathway inhibitor MK0752 |
|---|---|
| Sponsor | Cancer Research UK |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study Of MK-0752 In Combination With Tamoxifen Or Letrozole to Treat Early Stage Breast Cancer (PHASE4)
- A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027) (PHASE1)
- A Clinical Study to Determine Biomarkers of Response to a Gamma Secretase Inhibitor (PHASE1)
- MK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage III and IV Pancreatic Cancer That Cannot Be Removed by Surgery (PHASE1)
- Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049) (PHASE1)
- A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013) (PHASE1)
- A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014) (PHASE1)
- Phase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Notch signaling pathway inhibitor MK0752 CI brief — competitive landscape report
- Notch signaling pathway inhibitor MK0752 updates RSS · CI watch RSS
- Cancer Research UK portfolio CI